HLA-DRB3/4/5-based susceptibility profiles in nivolumab-induced type 1 diabetes and interstitial lung disease. - Nishikido S; Mishima H; Yoshiura KI; Sakamoto N; Ishimoto H; Morimoto S; Horie I; Akazawa S; Haraguchi A; Tsujiguchi H; Hara A; Tajima A; et al. (Frontiers in immunology, 2026)